Labcorp, Charles River and FDA Announce Research Collaboration to Advance Preclinical Methods for Evaluating Drug Abuse Potential
Article excerpt
Highlighted: the sentence this signal was extracted from
Research collaboration aims to strengthen the science used to assess whether new medicines could be abused, supporting safer drug development and more informed regulatory decisions BURLINGTON, N.C., Oct. 22, 2026 /PRNewswire/ -- Labcorp (NYSE: LH ), a global leader of innovative and comprehensive laboratory services, today announced a collaboration with the U.S. Food and Drug Administration (FDA) and Charles River Laboratories to advance the science used to evaluate a medicine's abuse potential, or the likelihood that it could be abused. The research aims to support safer drug development and more informed regulatory decisions. The collaboration brings together complementary expertise from industry and government. Labcorp will contribute its experience conducting regulatory abuse potential studies, while FDA scientists will conduct data analysis and contribute regulatory science expertise. Together, the organizations aim to advance the science used to evaluate the risk that a medicine could be abused using harmonized behavioral economics methodology to quantify and rank abuse potential. "This research has the potential to improve how abuse-related risks are evaluated and inform decisions throughout drug development and regulatory review," said Brian Caveney, M.D., EVP and president, biopharma laboratory services and chief medical and scientific officer, Labcorp. "Ultimately...
Keep reading with a free account
The rest of this article, and every signal for Labcorp, is in your free account.
